XULTOPHY ( Liraglutide) $469 | Certified Canadian Pharmacy

Description

XULTOPHY (insulin degludec and liraglutide) is a prescription medication prescribed to improve glycemic control in people who have type 2 diabetes mellitus.

People with type 2 diabetes mellitus still produce insulin, but their bodies have become resistant, requiring extra insulin. Insulin is the primary hormone that lowers blood sugar to normal levels.

Directions

Inject XULTOPHY subcutaneously once daily at the same time each day. XULTOPHY can be given with or without food.

XULTOPHY is dosed based on how much insulin a person normally uses. The possible starting doses are:

• 10 units insulin degludec and 0.36 mg liraglutide once daily
• 16 units insulin degludec and 0.58 mg liraglutide once daily

The maximum daily dose of XULTOPHY is 50 units insulin degludec and 1.8 mg liraglutide.

Ingredients

XULTOPHY contains two active ingredients: long-acting insulin and a GLP-1 receptor agonist.

Insulin degludec is a long-acting insulin that lasts about 24 hours for most patients.

Liraglutide is a GLP-1 receptor agonist that works by slowing down the gastrointestinal tract and by causing the pancreas to release extra insulin.

Interactions

Tell your doctor or pharmacist if you are taking any medications that mask the signs of hypoglycemia:

• Beta-blockers
• Clonidine
• Guanethidine
• Reserpine

The following drugs can affect the blood sugar of people with type 2 diabetes mellitus:

• Alcohol
• Atypical Antipsychotics
• Corticosteroids
• Disopyramide
• Diuretics
• Estrogens/Progesterones
• Fibrates
• Fluoxetine
• Isoniazid
• Lithium
• Monoamine Oxidase Inhibitors (MAOIs)
• Niacin
• Oral antidiabetic agents
• Pentoxifylline
• Phenothiazine derivatives
• Pramlintide
• Propoxyphene
• Protease inhibitors
• Salicylates
• Somatostatin Analogues
• Somatropin
• Sulfonamide Antibiotics
• Sympathomimetic agents
• Thyroid replacement medication

Since liraglutide slows down the gastrointestinal tract, use caution if you are taking the following medications:

• Acetaminophen (Tylenol)
• Antibiotics
• Oral contraceptives

Cautions

XULTOPHY cannot be used by anyone with a history of Medullary Thyroid Cancer (MTC). It is also contraindicated for people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Rotate injection sites to avoid lipodystrophy.

Do not use XULTOPHY in an insulin pump.

Side Effects

The most common adverse reactions from XULTOPHY may include:

• Allergic reactions
• Diarrhea
• Headache
• Hypoglycemia
• Nausea
• Upper respiratory tract infection

Manufacturer: Abbott

IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.